Form 4 Filing for Jonathan Zalevsky

Jonathan Zalevsky, Chief R&D Officer at NEKTAR THERAPEUTICS (NKTR), acquired 6,250 shares of Common Stock and 25,000 stock options on December 22, 2025. The Common Stock acquisition was part of a restricted stock unit (RSU) grant, which vests over four years in quarterly installments. The stock options also vest over four years, in monthly installments, with an exercise price of $43.48 and an expiration date of December 21, 2033. Both transactions are marked as direct acquisitions (D) with a transaction code (A) indicating acquisition. The post-transaction holdings for Common Stock are 25,221 shares, and for stock options, 25,000 options.